Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUILT-3.090: NANT SCC Vaccine in Advanced SCC
NCT03387111Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Jan 2018
- Primary completion
- Apr 2019
- Modality
- Adenoviral Vectors, DNA Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of haNK, nogapendekin alfa inbakicept, aldoxorubicin, ETBX-011, ETBX-021 in squamous cell carcinoma (SCC), sponsored by ImmunityBio, Inc.. Started Jan 2018; status: terminated.
02
Drugs
haNKnogapendekin alfa inbakiceptaldoxorubicinETBX-011ETBX-021
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT03387111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387111.